Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David K Packham

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 2, 2020
Erratum to: Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Exploratory Analyses from Three Randomized, Multi-Dose, Placebo-Controlled TrialsSimon D Roger, Bruce S Spinowitz, Edgar V Lerma, et al.
Nephron. Clinical Practice|February 5, 2011
Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathyDavid K Packham, Sara E Ivory, Anne T Reutens, et al.
The New England Journal of Medicine|November 22, 2014
Sodium zirconium cyclosilicate in hyperkalemiaDavid K Packham, Henrik S Rasmussen, Philip T Lavin, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 24, 2005
Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal functionCraig L Nelson, Connie S Karschimkus, George Dragicevic, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 5, 2011
Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) databaseDavid K Packham, Tahira P Alves, Jamie P Dwyer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 8, 2020
Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 studySimon D Roger, Philip T Lavin, Edgar V Lerma, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 22, 2019
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 StudyBruce S Spinowitz, Steven Fishbane, Pablo E Pergola, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2011
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trialEdmund J Lewis, Julia B Lewis, Tom Greene, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2011
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathyDavid K Packham, Rory Wolfe, Anne T Reutens, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2011
Pyridorin in type 2 diabetic nephropathyEdmund J Lewis, Tom Greene, Samuel Spitalewiz, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 2, 2020
Erratum to: Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Exploratory Analyses from Three Randomized, Multi-Dose, Placebo-Controlled TrialsSimon D Roger, Bruce S Spinowitz, Edgar V Lerma, et al.
Nephron. Clinical Practice|February 5, 2011
Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathyDavid K Packham, Sara E Ivory, Anne T Reutens, et al.
The New England Journal of Medicine|November 22, 2014
Sodium zirconium cyclosilicate in hyperkalemiaDavid K Packham, Henrik S Rasmussen, Philip T Lavin, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 24, 2005
Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal functionCraig L Nelson, Connie S Karschimkus, George Dragicevic, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 5, 2011
Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) databaseDavid K Packham, Tahira P Alves, Jamie P Dwyer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 8, 2020
Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 studySimon D Roger, Philip T Lavin, Edgar V Lerma, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 22, 2019
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 StudyBruce S Spinowitz, Steven Fishbane, Pablo E Pergola, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2011
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trialEdmund J Lewis, Julia B Lewis, Tom Greene, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2011
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathyDavid K Packham, Rory Wolfe, Anne T Reutens, et al.
Journal of the American Society of Nephrology : JASN|October 29, 2011
Pyridorin in type 2 diabetic nephropathyEdmund J Lewis, Tom Greene, Samuel Spitalewiz, et al.
Pageof 2